Literature DB >> 24725689

Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group.

Tim Illidge1, Lena Specht2, Joachim Yahalom3, Berthe Aleman4, Anne Kiil Berthelsen5, Louis Constine6, Bouthaina Dabaja7, Kavita Dharmarajan3, Andrea Ng8, Umberto Ricardi9, Andrew Wirth10.   

Abstract

Radiation therapy (RT) is the most effective single modality for local control of non-Hodgkin lymphoma (NHL) and is an important component of therapy for many patients. Many of the historic concepts of dose and volume have recently been challenged by the advent of modern imaging and RT planning tools. The International Lymphoma Radiation Oncology Group (ILROG) has developed these guidelines after multinational meetings and analysis of available evidence. The guidelines represent an agreed consensus view of the ILROG steering committee on the use of RT in NHL in the modern era. The roles of reduced volume and reduced doses are addressed, integrating modern imaging with 3-dimensional planning and advanced techniques of RT delivery. In the modern era, in which combined-modality treatment with systemic therapy is appropriate, the previously applied extended-field and involved-field RT techniques that targeted nodal regions have now been replaced by limiting the RT to smaller volumes based solely on detectable nodal involvement at presentation. A new concept, involved-site RT, defines the clinical target volume. For indolent NHL, often treated with RT alone, larger fields should be considered. Newer treatment techniques, including intensity modulated RT, breath holding, image guided RT, and 4-dimensional imaging, should be implemented, and their use is expected to decrease significantly the risk for normal tissue damage while still achieving the primary goal of local tumor control.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24725689     DOI: 10.1016/j.ijrobp.2014.01.006

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  64 in total

Review 1.  Consolidative Radiation in DLBCL: Evidence-Based Recommendations.

Authors:  David C Hodgson; N George Mikhaeel
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

2.  Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.

Authors:  Michael A Spinner; Vanessa E Kennedy; John S Tamaresis; Philip W Lavori; Sally Arai; Laura J Johnston; Everett H Meyer; David B Miklos; Lori S Muffly; Robert S Negrin; Andrew R Rezvani; Judith A Shizuru; Wen-Kai Weng; Richard T Hoppe; Samuel Strober; Robert Lowsky
Journal:  Blood Adv       Date:  2019-08-27

3.  ISRT: a new radiation therapy for malignant lymphomas: Introduction to the review article by Specht and Yahalom.

Authors:  Keisuke Sasai; Masahiko Oguchi
Journal:  Int J Clin Oncol       Date:  2015-07-11       Impact factor: 3.402

Review 4.  The concept and evolution of involved site radiation therapy for lymphoma.

Authors:  Lena Specht; Joachim Yahalom
Journal:  Int J Clin Oncol       Date:  2015-07-07       Impact factor: 3.402

5.  Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.

Authors:  Austin J Sim; Michael D Jain; Nicholas B Figura; Julio C Chavez; Bijal D Shah; Farhad Khimani; Aleksandr Lazaryan; Gabriel Krivenko; Marco L Davila; Hien D Liu; Aaron D Falchook; Saurabh Dahiya; Aaron P Rapoport; Sungjune Kim; Frederick L Locke; Timothy J Robinson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-06-05       Impact factor: 7.038

6.  Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.

Authors:  Chelsea C Pinnix; Jillian R Gunther; Sarah A Milgrom; Ruben J Cruz Chamorro; L Jeffrey Medeiros; Joseph D Khoury; Behrang Amini; Sattva Neelapu; Hun J Lee; Jason Westin; Nathan Fowler; Loretta Nastoupil; Bouthaina Dabaja
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-02-12       Impact factor: 7.038

7.  [Survival Benefit with Consolidative Radiotherapy in Early-Stage Diffuse Large B‑Cell Lymphoma patients].

Authors:  Khaled Elsayad; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2016-07       Impact factor: 3.621

8.  A phase III randomized controlled trial of radiation dose optimization in non-Hodgkin lymphoma-diffuse large B-cell lymphoma (DOBL study): Study protocol and design.

Authors:  Jayant S Goda; Shirly C Lewis; Siddartha Laskar; Sadhna Kannan; Nehal Khanna; Hasmukh Jain; Bhausaheb Bagal; Sridhar Epari
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-14

9.  Rainbow IMRT and Volumetric Imaging for Anterior Mesenteric Targets.

Authors:  Alison K Yoder; Jillian R Gunther; Sarah A Milgrom; Mary Pham; Donald Hancock; Kelli McSpadden; John Garcia; Dragan Mirkovic; Bouthaina S Dabaja; Chelsea C Pinnix
Journal:  Pract Radiat Oncol       Date:  2019-01-29

10.  Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations.

Authors:  George Daniel Grass; Matthew N Mills; Kamran A Ahmed; Casey L Liveringhouse; Michael E Montejo; Timothy J Robinson; Julio C Chavez; Louis B Harrison; Sungjune Kim
Journal:  Leuk Lymphoma       Date:  2018-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.